| buprenorphine |
drug |
10 |
9 |
BUP, buprenorphine prescription status, buprenorphine treatment days, buprinorphine, subcutaneous buprinorphine |
| bupropion |
drug |
11 |
9 |
BUP, Wellbutrin, Zyban, bupropion 150 mg SR-sustained release tablets, bupropion SR, bupropion sustained-release, buproprion |
| burst firing |
phenotype |
2 |
— |
burst firing |
| BXD mice |
cohort |
2 |
1 |
BXD, BXD mice |
| C12orf51 |
gene |
3 |
3 |
chromosome 12 ORF 51 |
| C15orf53 |
gene |
3 |
2 |
C15ORF53 region |
| C17orf58 |
gene |
2 |
1 |
|
| C1qa |
gene |
3 |
2 |
C1qa |
| C1qb |
gene |
3 |
1 |
C1qb |
| C4orf17 |
gene |
2 |
2 |
|
| C57BL/6J |
cohort |
43 |
24 |
B6, B6 mice, C57, C57/Bl6 background, C57BL mice, C57BL/6, C57BL/6 J, C57BL/6 mice, C57BL/6 mouse strain, C57BL/6 strain mice, C57BL/6J, C57BL/6J mice, C57BL/6J mouse, C57BL/6J mouse strain, C57BL/6N, C57BL/6j, C57BL/6j mice, C57BL6J, C57Bl/6J, C57Bl/6j mice, C57Bl6J, EtOH-preferring C57BL/6, Jackson C57BL/6j, WT mice, adult C57BL/6 mouse, alcohol-preferring C57BL/6J |
| C57BL/6N |
cohort |
2 |
1 |
C57BL/6N |
| Ca2+ |
drug |
14 |
10 |
Ca2+, Ca2+ currents, Ca2+ ions, Calcium, Calcium ion, Ca²⁺, [Ca2+], calcium, calcium ion, free Ca2+ |
| CaCl2 |
drug |
11 |
6 |
calcium chloride |
| CACNA1A |
gene |
2 |
1 |
|
| CACNA1C |
gene |
16 |
13 |
CACN1AC, CACNA1C38, CaV1.2, Cav1.2, Cav1.2 α subunit, L-type calcium channel CACN1AC, L-type voltage-gated Ca2+ channel α1c, TS-CaV1.2, Timothy Syndrome gene, alpha 1C subunit of the L-type voltage-gated calcium channel, calcium channel, voltage dependent, L type, α-1C subunit, calcium channel, voltage-dependent, L type, alpha 1C subunit, calcium channel, voltage-dependent, L type, α 1C subunit, calcium voltage-gated channel subunit alpha1 C, voltage-dependent L-type calcium channel subunit alpha-1C, α1c |
| CACNA1E |
gene |
3 |
2 |
|
| CACNA2D1 |
gene |
2 |
2 |
|
| CACNA2D2 |
gene |
3 |
3 |
Calcium subunit CACNA2D2, calcium channel complex subunit gene |
| CACNB2 |
gene |
3 |
3 |
Cavβ2 subunit |
